This is an older chart I found of sales growth in Acadia’s other drug called Nuplazid..
Nuplazid did US$142m net sales in the most recent quarter. After listening to the update from Acadia this morning, one thing is clear, these guys have a very well established and wide reaching distribution and marketing ability across the USA. Daybue sales have started much stronger than Nuplazid at the same point in their respective timelines. If we have even half the growth rate of Nuplazid, we’re looking at a snowballing monster on our hands.
GLTA holders.
Acadia, page-442
-
- There are more pages in this discussion • 236 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 582 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.36pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable